Optilume BPH Catheter System offers a safe and effective treatment for benign prostatic hyperplasia

Treatment with the recently approved, minimally invasive Optilume BPH device improves urinary symptoms while preserving sexual function in men with benign prostatic hyperplasia (BPH), concludes a randomized trial in the September issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA).

CD70 CAR-T by UTC Therapeutics for Marginal Zone B-cell Lymphoma: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

August 10, 2023

Tepotinib Gains Full Approval for Metastatic NSCLC

The FDA transitioned the small-molecule inhibitor tepotinib (Tepmetko) from accelerated to full approval for metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping

February 17, 2024

Reflecting on Psychedelics in 2023 – Psychedelic Alpha

Like many things, 2023 simultaneously passed in a flash yet also seems like an era ago. When I looked back through our coverage in preparation

January 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.